Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | MAP2K1 C121S MAP2K1 P124R |
| Therapy | Trametinib |
| Indication/Tumor Type | melanoma |
| Response Type | predicted - sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| MAP2K1 C121S MAP2K1 P124R | melanoma | predicted - sensitive | Trametinib | Case Reports/Case Series | Actionable | In a clinical case study, Mekinist (trametinib) resulted in a partial response after two months of treatment in a patient with melanoma harboring MAP2K1 C121S and MAP2K1 P124R (PMID: 36901951). | 36901951 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (36901951) | Response and Resistance to Trametinib in MAP2K1-Mutant Triple-Negative Melanoma. | Full reference... |